Anti-Cancer MAbS Market Report 2026

Anti-Cancer MAbS Market Overview

• Anti-Cancer MAbS market size has reached to $71.25 billion in 2025 • Expected to grow to $112.41 billion in 2030 at a compound annual growth rate (CAGR) of 9.5% • Growth Driver: Rising Global Cancer Prevalence Fuels Anticancer monoclonal antibodies (mAbs) Market Growth • Market Trend: Innovative Approaches In Anticancer Monoclonal Antibodies Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anti-Cancer MAbS Market?

Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth, and spread. The main types of anti-cancer mAbs are murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine refers to a type of monoclonal antibody (mAb) that is a laboratory-made copy of a single antibody, produced by a single B cell, derived from mice or rats, they are used to bind to a specific antigen. These are used in various applications such as blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer and others and are used in hospitals, research institutes, and others.

What Is The Anti-Cancer MAbS Market Growth Forecast?

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $112.41 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to growth in personalized cancer medicine, expansion of biosimilar mAbs, rising oncology healthcare spending, advances in antibody engineering, increasing access to biologic therapies. Major trends in the forecast period include rising adoption of targeted immunotherapies, expansion of humanized and bispecific antibodies, growing use of combination cancer therapies, increasing focus on precision oncology, improved manufacturing scalability of mAbs.

What Is The Driver Of The Anti-Cancer MAbS Market?

The increasing prevalence of cancer across the globe is expected to propel the growth of the anticancer mAbs market going forward. Cancer refers to a group of diseases characterised by uncontrolled cell growth with the potential to invade and harm healthy bodily tissue. The increasing prevalence of cancer is due to ageing populations, lifestyle changes, environmental exposures, and advances in diagnostic technology that lead to higher detection rates. Anticancer monoclonal antibodies (mAbs) are designed to bind to specific proteins on cancerous cells, using genetically engineered versions of the immune system’s own antibodies to target and destroy those cells; thus, increasing cancer prevalence increases demand for the anticancer mAbs market. For instance in February 2024 accroding to the World Health Organization (WHO) a Switzerland-based United Nations agency in 2050, new cancer cases are projected to exceed 35 million, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer across the globe is driving the growth of the anticancer mAbs market.

Key Players In The Global Anti-Cancer MAbS Market

Major companies operating in the anti-cancer mabs market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, ADC Therapeutics, MacroGenics Inc., Zymeworks Inc.

Global Anti-Cancer MAbS Market Trends and Insights

Major companies operating in the anti-cancer monoclonal antibodies (mAbs) market are focusing on developing innovative solutions, such as early-phase clinical trials, to advance novel therapeutic candidates and strengthen their competitive position. Clinical trials refer to structured research studies conducted in human participants to evaluate the safety, dosing, and therapeutic effectiveness of new medical interventions, including targeted antibodies and radioimmunotherapies. For instance, in April 2023, Y-mAbs Therapeutics Inc., a US-based clinical biopharmaceutical company, launched a Phase I clinical trial evaluating GD2-SADA, a pre-targeted radioimmunotherapy designed for GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. The therapy uses a two-step mechanism in which the SADA protein first binds selectively to GD2-expressing tumor cells, followed by administration of the radioactive ligand 177Lu-DOTA that attaches to the SADA protein to deliver targeted radiation, aiming to maximize tumor cell destruction while minimizing radiation exposure to healthy tissues.

What Are Latest Mergers And Acquisitions In The Anti-Cancer MAbS Market?

In June 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.8 billion. This acquisition strengthens Merck’s immunology portfolio by integrating Prometheus’s lead candidate PRA023 (now MK-7240), a monoclonal antibody targeting TL1A involved in autoimmune conditions such as ulcerative colitis and Crohn’s disease. It further enhances Merck’s pipeline with advanced biologics and supports expansion into precision immunology through Prometheus’s biomarker-driven development platform. Prometheus Biosciences Inc. is a US-based clinical-stage biotechnology company that develops monoclonal antibody therapies.

What Defines the Anti-Cancer MAbS Market?

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-Cancer MAbS Market Report 2026?

The anti-cancer mabs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer mabs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.